Bacteriophage Proteome: Insights and Potentials of an Alternate to Antibiotics

Introduction The mounting incidence of multidrug-resistant bacterial strains and the dearth of novel antibiotics demand alternate therapies to manage the infections caused by resistant superbugs. Bacteriophages and phage=derived proteins are considered as potential alternates to treat such infections, and have several applications in health care systems. The aim of this review is to explore the hidden potential of bacteriophage proteins which may be a practical alternative approach to manage the threat of antibiotic resistance. Results Clinical trials are in progress for the use of phage therapy as a tool for routine medical use; however, the existing regulations may hamper their development of routine antimicrobial agents. The advancement of molecular techniques and the advent of sequencing have opened new potentials for the design of engineered bacteriophages as well as recombinant bacteriophage proteins. The phage enzymes and proteins encoded by the lysis cassette genes, especially endolysins, holins, and spanins, have shown plausible potentials as therapeutic candidates. Conclusion This review offers an integrated viewpoint that aims to decipher the insights and abilities of bacteriophages and their derived proteins as potential alternatives to antibiotics.

Automated summary

Bacteriophages and their derived proteins are considered as potential alternatives to antibiotics to manage infections caused by multidrug-resistant bacterial strains. Clinical trials are ongoing for phage therapy, but existing regulations may hinder their development as routine antimicrobial agents. Advancements in molecular techniques and sequencing offer new potentials for engineered bacteriophages and recombinant bacteriophage proteins.